Revenue
No reported data
Indaptus Therapeutics, Inc. (INDP)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $9.3M | $7.3M | $7.6M | $6.3M | $2.5M | $2.7M |
| Operating expenses | $19.8M | $15.4M | $16.4M | $14.9M | $7.7M | $3.6M |
| Operating income | −$19.8M | −$15.4M | −$16.4M | −$14.9M | −$7.7M | −$3.6M |
| Net income | −$20.8M | −$15.0M | −$15.4M | −$14.3M | −$7.7M | −$3.6M |
| Basic EPSper diluted share | -$21.58 | -$44.96 | -$1.83 | -$1.73 | -$1.89 | -$1.84 |
| Diluted EPSper diluted share | -$21.58 | -$44.96 | -$1.83 | -$1.73 | -$1.89 | -$1.84 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 23, 2026Form 4 | Lazar David E.Director | SellSeries AAA Convertible Non-Redeemable Preferred Stock · derivative | 700.0K | — | — | 0 |
| Mar 23, 2026Form 4 | Lazar David E.Director | SellSeries AA Convertible Non-Redeemable Preferred Stock · derivative | 196.8K | — | — | 103.2K |